COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg
Dysfunctional Uterine Bleeding
About this trial
This is an interventional other trial for Dysfunctional Uterine Bleeding
Eligibility Criteria
Inclusion Criteria:
1. Be pre-Menopausal females with regular menstrual cycles and > 30 years of age 2. Premenopausal at enrollment as determined by FSH measurement ≤ 60 IU/mL. 3. Endometrial thickness at pre-treatment less than 20 mm. 4. Diagnosis of Dysfunctional Uterine Bleeding and requiring endometrial ablation 5. Tumour negative cytology and histology 6. Appropriate sized uterus with no anatomic pathologies 7. Patient is not pregnant and does not wish to become pregnant in the future 8. Patient is willing to use a non-hormonal contraception method during the study, nor an intra-uterine device 9. Patient has no endocrine disorders, is not receiving hormonal therapies or non-steroidal anti-inflammatory medication. (prophylactic antibiotics can be administered according to the usual practice of the investigator) 10. Have the ability to understand the requirements of the study and is willing to provide written informed consent 11. Agree to abide by the study restrictions and return for the required assessments 12. Only patients which can be discontinued safely from contra-indicated medications discussed below in section 7.4 can be included in the study.
-
Exclusion Criteria:
- Be pregnant or have desire to conceive
- Have abnormal endometrial cytology as confirmed by histology
- Have active endometritis
- Have active pelvic inflammatory disease
- Have active sexually transmitted disease (STD), at the time of ablation. Note: Treatment of STD documented in the chart serves as sufficient evidence of infection resolution. Patient may be considered for study enrollment.
- Presence of bacteremia, sepsis, or other active systemic infection
- Have active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of inclusion
- Known/suspected gynecological malignancy within the past 5 years
- Known clotting defects or bleeding disorders
- Untreated/unevaluated cervical dysplasia
- Known/suspected abdominal/pelvic cancer
- Atypical Hyperplasia
- Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., myomectomy or classical cesarean section
- Currently on medications that could thin the myometrial muscle, such as long-term steroid use (except inhaler or nasal therapy for asthma)
- Currently on anticoagulants
- Have a known hypersensitivity to gonadotropin releasing hormone (GnRH), GnRH agonists, any LHRH agonists (e.g., leuprolide (Lupron®), goserelin ( Zoladex®) etc.) or to the PLGA polymers contained in the study formulation
- Have a severe liver disease (e.g., cirrhosis, chronic active hepatitis or chronic persistent hepatitis) or has persistent ALT, AST ˃ 2 X ULN, serum creatinine ˃ 2 X ULN, serum bilirubin ˃ 2 X ULN
- Have received an investigational drug or participated in a clinical trial within the last 30 days
- Have clinically serious and/or unstable concurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy
- Patients with BMI ˂ 18
- Anticoagulated patients with INR ≥ 2
Patients with a history of QT prolongation, congenital long QT syndrome, electrolyte abnormalities, CHF, or concurrent administration with QT prolonging drugs or QTc ˃450 msec.
-
Sites / Locations
- Central Military Hospital
- LLC Medical Center
- Maternity Hospital no 3
- Center for Innovative Medical Technologies of the National Academy of Sciences
- City Clinical Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Pepti 3.6 treatment
Zoladex 3.6 mg treatment
Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28